The Liver Meeting, The 62nd Annual Meeting of the American Association for the Study of Liver Diseases

November 4-8, 2011 - San Francisco

AASLD 2011: Long-Term Tenofovir for Chronic Hepatitis B Reduces Liver Inflammation and Cirrhosis

Most chronic hepatitis B patients who maintain viral suppression on tenofovir (Viread) for 5 years experience improvement in liver histology, including regression of cirrhosis, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.alt

Read more:

AASLD 2011: New NS5A Inhibitor PPI-461 Shows Promising Safety and Efficacy in Brief Study

Presidio's hepatitis C virus (HCV) NS5A inhibitor candidate PPI-461 demonstrated rapid and potent antiviral activity in a 3-day study, but resistance may be a problem, according to a study presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.alt

Read more:

AASLD 2011: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders

A dual antiviral regimen containing the novel hepatitis C virus (HCV) NS5A inhibitor daclatasvir (BMS-790052) plus the NS3 protease inhibitor asunaprevir (BMS-650032) -- without interferon -- produced rapid and sustained viral suppression in Japanese prior null responders with HCV genotype 1b, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.alt

Read more:

All-Oral Regimens -- The Future of Hepatitis C Treatment

Attendees at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco got a glimpse of the future of chronic hepatitis C therapy, as several researchers presented data from studies of all-oral direct-acting antiviral (DAA) regimens -- without interferon and its notoriously difficult side effects.

NEJM: High SVR Rate with Daclatasvir + Asunaprevir

AASLD: Daclatasvir + Asunaprevir Suppresses HCV in Null Responders

AASLD: PSI-7977 + Ribavirin Cures Hepatitis C in 12 Weeks

AASLD: BI 201355 + BI 201127 + Ribavirin Looks Good in SOUND-C

alt

Read more:

AASLD 2011: PSI-7977 plus Ribavirin Can Cure Hepatitis C in 12 Weeks without Interferon

An all-oral dual regimen containing Pharmasset's hepatitis C virus (HCV) polymerase inhibitor PSI-7977 plus ribavirin produced 100% sustained response at 12 weeks in previously untreated people with HCV genotypes 2 or 3, according to findings from the ELECTRON study reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.alt

Read more: